Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Annabell F. Leske"'
Autor:
Bernard Flynn, Clayton A. Matthews, Michael O'Callaghan, Allison Hall, Jelena Gasic, Donna Beaumont, Tina C. Lavranos, Annabell F. Leske, Gabriel Kremmidiotis
Vascular disruption agents (VDA) cause occlusion of tumor vasculature, resulting in hypoxia-driven tumor cell necrosis. Tumor vascular disruption is a therapeutic strategy of great potential; however, VDAs currently under development display a narrow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87b4d9f87ffff55b4fc8503c2bba2862
https://doi.org/10.1158/1535-7163.c.6531642.v1
https://doi.org/10.1158/1535-7163.c.6531642.v1
Autor:
Jayesh Desai, Mark A. Rosen, Shirley S. Wong, Clayton A. Matthews, Annabell F. Leske, Gabriel Kremmidiotis, Geoff Chong, David C. Bibby, Danny Rischin
Purpose: To determine the recommended phase II dose and evaluate the safety and toxicity profile and pharmacokinetic (PK) and pharmacodynamic (PD) effects of BNC105P, an inhibitor of tubulin polymerization that has vascular disrupting and antiprolife
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f1bbb3cae0a7545d34a0051d68e8d2f
https://doi.org/10.1158/1078-0432.c.6519413
https://doi.org/10.1158/1078-0432.c.6519413
Autor:
Bernard Flynn, Clayton A. Matthews, Michael O'Callaghan, Allison Hall, Jelena Gasic, Donna Beaumont, Tina C. Lavranos, Annabell F. Leske, Gabriel Kremmidiotis
Adobe PDF - Supplementary_Data.pdf from BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99dbc5fd464c1e0c22a679fb4777ae08
https://doi.org/10.1158/1535-7163.22484895.v1
https://doi.org/10.1158/1535-7163.22484895.v1
Autor:
Jayesh Desai, Mark A. Rosen, Shirley S. Wong, Clayton A. Matthews, Annabell F. Leske, Gabriel Kremmidiotis, Geoff Chong, David C. Bibby, Danny Rischin
PDF file - 66K, The pharmacokinetic parameters of BNC105 and BNC105P.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0af603ef437e39000092338ce897079a
https://doi.org/10.1158/1078-0432.22442744.v1
https://doi.org/10.1158/1078-0432.22442744.v1
Autor:
Jayesh Desai, Mark A. Rosen, Shirley S. Wong, Clayton A. Matthews, Annabell F. Leske, Gabriel Kremmidiotis, Geoff Chong, David C. Bibby, Danny Rischin
PDF file - 191K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5289dd61852f228ac58df7d96ec75487
https://doi.org/10.1158/1078-0432.22442747
https://doi.org/10.1158/1078-0432.22442747
Autor:
Annabell F. Leske, Julie Martyn, Tina C. Lavranos, David Espinoza, Dirkje W. Sommeijer, Jose Iglesias, Philip Beale, Elizabeth E. Doolin, Jeremy Simpson, Danny Rischin, Jeff C. Goh, Gabriel Kremmidiotis, Emma C. Rossi, Kristina Lindemann, Anneso S. Veillard, Martin R. Stockler, Michelle Margaret Vaughan, Meaghan Tenney
Publikováno v:
Cancer chemotherapy and pharmacology, 83(1), 97-105. Springer Verlag
Purpose: The primary objective of this study was to determine the recommended dose of the vascular disrupting agent, BNC105P, in combination with gemcitabine and carboplatin in patients with ovarian cancer in first or second relapse with a minimum 4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1505eabd827e65c42487a3157a87ae2b
https://pure.amc.nl/en/publications/phase-i-study-of-bnc105p-carboplatin-and-gemcitabine-in-partially-platinumsensitive-ovarian-cancer-patients-in-first-or-second-relapse-anzgog1103(bec4efc5-2158-432c-b127-5dc2abc25aa3).html
https://pure.amc.nl/en/publications/phase-i-study-of-bnc105p-carboplatin-and-gemcitabine-in-partially-platinumsensitive-ovarian-cancer-patients-in-first-or-second-relapse-anzgog1103(bec4efc5-2158-432c-b127-5dc2abc25aa3).html
Autor:
Richard C. Lauer, Ravindran Kanesvaran, Gabriel Kremmidiotis, Harry A. Drabkin, Thomas E. Hutson, Jose Iglesias, Timothy Breen, Alexander Starodub, Christopher Sweeney, Stephen Lane Richey, Brian A. Costello, Shailender Bhatia, David C. Bibby, Jeremy Simpson, Annabell F. Leske, Sumanta K. Pal, Ralph J. Hauke, Elizabeth E. Doolin, Arun Azad, Guru Sonpavde, Noah M. Hahn, John Sarantopoulos
Publikováno v:
Clinical Cancer Research. 21:3420-3427
Purpose: BNC105P inhibits tubulin polymerization, and preclinical studies suggest possible synergy with everolimus. In this phase I/II study, efficacy and safety of the combination were explored in patients with metastatic renal cell carcinoma (mRCC)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0b0b215f9b26cd05e303e8eb87359e6
https://doi.org/10.1158/1078-0432.ccr-14-3370
https://doi.org/10.1158/1078-0432.ccr-14-3370
Autor:
Daniel J. Inglis, Chloe K. Brown, Tina C. Lavranos, Gabriel Kremmidiotis, Annabell F. Leske, Allison J Hall, Donna M. Beaumont
Publikováno v:
Cancer Biology & Therapy. 15:1552-1560
BNC105 is a tubulin targeting compound that selectively disrupts vasculature within solid tumors. The severe tumor hypoxia and necrosis that ensues translates to short term tumor growth inhibition. We sought to identify the molecular and cellular eve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a01c1827bb4cbe42fff8f8ee5b023ff
https://doi.org/10.4161/15384047.2014.956605
https://doi.org/10.4161/15384047.2014.956605
Autor:
David K. Chalmers, Jason H. Chaplin, Tina C. Lavranos, Bernard L. Flynn, Annabell F. Leske, Dharam Paul, Gurmit S. Gill, Damian Grobelny, Ernest Hamel, Edmund Kostewicz, Julia Morizzi, M. Katherine Jung, David M. Shackleford, Gabriel Kremmidiotis, Susan A. Charman
Publikováno v:
Journal of Medicinal Chemistry. 54:6014-6027
A structure-activity relationship (SAR) guided design of novel tubulin polymerization inhibitors has resulted in a series of benzo[b]furans with exceptional potency toward cancer cells and activated endothelial cells. The potency of early lead compou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e50248d4cd2d0cae01b413445e930e2a
https://doi.org/10.1021/jm200454y
https://doi.org/10.1021/jm200454y
Autor:
Donna M. Beaumont, Annabell F. Leske, Bernard L. Flynn, Michael O'Callaghan, Tina C. Lavranos, Clayton A. Matthews, Jelena Gasic, Gabriel Kremmidiotis, Allison J Hall
Publikováno v:
Molecular Cancer Therapeutics. 9:1562-1573
Vascular disruption agents (VDA) cause occlusion of tumor vasculature, resulting in hypoxia-driven tumor cell necrosis. Tumor vascular disruption is a therapeutic strategy of great potential; however, VDAs currently under development display a narrow
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fed867ec9db1ae1224bf0dbe0fdad036
https://doi.org/10.1158/1535-7163.mct-09-0815
https://doi.org/10.1158/1535-7163.mct-09-0815